Fusion Proteins for Treating Cancer and Autoimmune Diseases
Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
KAHR is developing immuno-oncology drug candidates for the treatment of multiple types of cancer. Its lead product, DSP107, is a CD47x41BB targeting compound that simultaneously targets cancer cells, weakens their innate defenses, and activates an effective local response of both innate and adaptive immunity.
KAHRs technology platform is based on multifunctional immuno-recruitment proteins (MIRP) that utilize overexpression of checkpoint antigens on cancer cells to selectively target and bind to the tumor. MIRPs bridge cancer cells to immune cells to produce a targeted synergistic effect by combining immune checkpoint inhibition with localized immune cell activation, unmasking cancer cell camouflage to enable innate immune response while recruiting the adaptive immune system to bind and selectively kill the cancer cells.
In August 2020, KAHR Medical received FDA clearance to begin clinical trials on its immunotherapy drug to battle cancer.